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Uncontrolled allergic and non-allergic rhinitis have a major impact on work productivity and 
absenteeism [1]. The Work Productivity and Activity Impairment Allergic Specific Questionnaire 
(WPAI-AS) has been used in many studies [2-7]. Work productivity impairment assessed using the 
WPAI-AS has been associated with allergic rhinitis (AR) severity [7]. We have found using mobile 
technology based visual analogue scales (VAS) that work productivity is impaired in moderate/severe 
AR [8].   
MASK-rhinitis (MACVIA-ARIA Sentinel NetworK for allergic rhinitis) is an ICT system centred 
around the patient [9] using a mobile phone app (Allergy Diary). App users are asked to complete a 
short demographic questionnaire and WPAI-AS thus providing baseline characteristics of their 
disease. The Allergy Diary has been launched in 21 countries. 
In order to better assess the loss of work productivity in AR, we tested the WPAI-AS using the 
Allergy Diary. 
A cross-sectional study was carried out from June 1, 2016 to July 31, 2017 in all consecutive users of 
the Allergy Diary (12,636) who filled in the WPAI-AS. The description of the Allergy Diary is 
reported in previous papers [8,10]. The app collects information on AR symptoms experienced (nasal 
and ocular), disease type (intermittent/persistent), how symptoms impact users’ lives, and type(s) of 
AR treatment used. The system has been deployed in 21 countries and in 16 languages (translated and 
back-translated, culturally adapted and legally compliant). The data are anonymized, except for 
geolocalized data that are never totally anonymous. An Independent Review Board approval was not 
needed. 
The electronic form of the WPAI-AS Questionnaire was applied in the seven available languages (i.e. 
English, French, German, Italian, Polish, Portuguese and Spanish) (8, 10) according to the package 
obtained from Reilly and associates (www.reillyassociates.net/WPAI_General.html). The percentages 
of impairment due to allergy for daily activities (Q9: degree allergy affected regular activities) or work 
productivity (Q4: degree allergy affected productivity while working) were the outcomes used. 
Since the results were not normally distributed for Q4 and Q9 (Shapiro-Wilk test), medians and 
interquartile ranges, percentiles and non-parametric tests were used. 
 
Of the 12,636 registered users, 1,017 filled in the WPAI-AS Q9 and 698 the Q4 (Table 1 online). 
There were 629 women (61%) and 405 men (39%), with a mean age of 26 ± 16 years. The repartition 
of countries was: 
• Austria  7 users 
• Australia  6 
• Brazil  198 
• Canada  3 
• France  126 
• Germany  96 
• Italy  126 
• Mexico  85 
• Poland  43 
• Portugal  294 
• Spain  66 
• Switzerland 89 
• UK   73 
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Similar levels of WPAI-AS percentages of impairment were found for Q4 (N= 698, median and 25-75 
percentiles: 20, 4-50) and for Q9 (N= 1,017; 17, 3-45). 
There was a highly significant correlation between the two questions (Figure 1). For a Q4 percentage 
of impairment of over 50, all but one user reported no impairment of work productivity. In users with 
Q4 ≥50, 18% had a Q9<50.  
Analysis of data from this pilot of establishing an ICT-based care system for AR found that the level 
of work impairment is highly correlated with the degree that allergy affected regular activities using 
the two validated questions of the WPAI-AS on global and work impairment.  
The strengths and limitations of this study are those of mobile technology lengthily discussed 
previously [8,10].  A key limitation was that there was a lack of patient characterization, which is 
impossible using an app. However, every observational study we have performed using the Allergy 
Diary has confirmed the potential to identify users with severe disease. It is likely that mobile 
technology will become a very important tool of the understanding and management of AR. 
The WPAI-AS scores observed in the study are lower than those reported in patients selected by 
physicians [2-7]. This is because many users have mild rhinitis whereas in clinical trials or in patients 
selected by physicians AR is usually more severe.   
The results of the study are in line with two previous studies using the same App. These three studies 
used different, but complementary tools. In the first study, a global question was assessed at baseline 
(“How my symptoms affect my school or work?”) [10] and it was found that impairment was 
associated with troublesome symptoms, ocular symptoms and nasal obstruction. In the second study, 
VAS work was correlated with global allergy symptoms (N=5,678 days, Rho=0.82), rhinitis 
(Rho=0.80), eye symptoms (Rho=0.70) and asthma (Rho=0.56). In this third study, there is a highly 
significant correlation between the Q4 (degree allergy affected productivity while working) and Q9 
(degree allergy affected regular activities) WPAI-AS questions. Together, the findings from these 
studies indicate that three different tools used in a large number of countries and languages with 
cultural differences give very similar results. There is a very strong correlation between the severity of 
rhinitis and work productivity. However, as found in the three studies, some work impairment is also 
found in users with milder rhinitis symptoms. 
Work productivity is a major problem in rhinitis sufferers. Those with severe symptoms have almost 
always some work impairment, but work impairment is not restricted to moderate and severe patients. 
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